Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.62 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.59 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 2/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E626 SCHEMBL8655976 | 1.00 | NT5E (0.67) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL28224063 | 1.00 | NT5E (0.67) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| E626 SCHEMBL16245477 | 0.97 | NT5E (0.71) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| E626 SCHEMBL6534995 | 0.94 | NT5E (0.60) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| Guanosine SCHEMBL1983917 | 0.93 | LMNA (0.64) | NT5ETGM2P2RY2P2RY4P2RY6 | |
| SCHEMBL18281060 | 0.92 | NT5E (0.71) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| SCHEMBL1983921 | 0.92 | NT5E (0.71) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| E626 SCHEMBL2775605 | 0.92 | NT5E (0.77) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL8611555 | 0.92 | TGM2 (0.62) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| SCHEMBL8616145 | 0.92 | TGM2 (0.62) | NT5ETGM2IMPDH2IMPDH1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| EP-4281058-A2 | FUNCTIONALIZED LONG-CHAIN CARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230173059-A1 | TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-08 | — | — | US | claimed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4149550-A1 | TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115768892-A | Herpes zoster vaccine comprising a TLR9 agonist | 戴纳瓦克斯技术公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115697389-A | Active boost immunization against tetanus, diphtheria and pertussis | 戴纳瓦克斯技术公司 | 2023-02-03 | — | — | CN | claimed |
| CN-114126593-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful for preventing or treating disease | 埃斯佩尔维塔治疗股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2021231942-A1 | TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-11-18 | — | — | WO | claimed |
| US-10799553-B2 | Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells | HUANG MALLEN (SE) | 2020-10-13 | — | — | US | claimed |
| CN-103961315-A | NUCLEIC ACID NANOPARTICLES AND USES THEREFOR | ANTERIOS INC | 2014-08-06 | — | — | CN | claimed |
| CN-1805758-B | Nucleic acid and cellular vaccine components | HUANG RANYANG | 2012-04-25 | — | — | CN | claimed |
| EP-1658097-B1 | NUCLEOTIDE AND CELLULAR VACCINE COMPOSITION | HUANG MALLEN (SE) | 2011-06-29 | — | — | EP | claimed |
| CN-101765423-A | Nucleic acid nanoparticles and uses thereof | ANTERIOS INC | 2010-06-30 | — | — | CN | claimed |
| US-20070071722-A1 | Nucleotide vaccine composition | HUANG MALLEN | 2007-03-29 | — | — | US | claimed |
| CN-1805758-A | Nucleotide and cellular vaccine composition | MALLEN HUANG (SE) | 2006-07-19 | — | — | CN | claimed |
| EP-1658097-A1 | NUCLEOTIDE AND CELLULAR VACCINE COMPOSITION | Huang, Mallen (SE) | 2006-05-24 | — | — | EP | claimed |
| WO-2004089413-A1 | NUCLEOTIDE AND CELLULAR VACCINE COMPOSITION | HUANG MALLEN (SE) | 2004-10-21 | — | — | WO | claimed |
| US-12024709-B2 | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | Actym Therapeutics, Inc. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20030118569-A1 | Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | NT5E 4240/4885TGM2 2734/4885IMPDH2 2232/4885 |
| US-20230173059-A1 | TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF | TLR3, TLR9, TLR1 | NT5E 1638/4885TGM2 2438/4885IMPDH2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.